# How a Digital Behavioral Health Game Reduced Depression in Adolescents

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/digital-behavioral-health-game-depression-adolescents/
> **Published:** 2026-08-23T14:27:32-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:47:02-04:00
> **Clinical Summary:** A digital behavioral health game depression adolescents trial showed modest reduction in depressive symptoms over 12 months in a school-based setting.

---

CED Clinical Relevance #79 Clinical Evidence Update This is a CONSORT-reported, active-controlled randomized clinical trial published in JAMA Network Open with 12-month follow-up, which clears the Clinical Evidence Update bar on its own methodological strength. [Cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) was one of several eligibility criteria (alongside alcohol, nicotine, other nonopioid substance use, or elevated depression/anxiety symptoms) rather than a study outcome, so its cannabis relevance is about the population served, not a cannabis-specific finding, and this post frames that distinction explicitly rather than overstating it.

Clinical Insight | CED Clinic
Researchers conducted a prespecified secondary analysis of a randomized clinical trial testing PlaySmart, a codesigned digital behavioral health game originally developed to prevent opioid misuse, against an active, attention-matched control among 532 adolescents recruited from 15 school-based health programs in Connecticut between October 2021 and February 2024. Eligible teens were 16 to 19 years old with no history of opioid misuse who reported past-30-day use of alcohol, cannabis, nicotine, or other nonopioid substances, or who screened positive for depressive or anxiety symptoms. Participants were randomized 1:1 to the six-week digital game intervention (n=269) or to a menu of commercially available games matched for time and attention (n=263), and were followed for 12 months. Depressive symptoms, measured with the PHQ-8, showed a significant group-by-time interaction, with intervention participants scoring 1.12 points lower than control participants at 12 months. Anxiety symptoms showed no significant difference. Intervention participants also reported more favorable beliefs about seeking psychological help immediately after gameplay, and an exploratory mediation analysis suggested this early belief shift partially explained the depression benefit at 6 months.

[Adolescent Mental Health](https://cedclinic.com/conduct-disorder-substance-use-disorders-teens/)Digital TherapeuticsDepressionSchool-Based HealthSubstance-Use Risk

Audience
Family physicians, pediatric and adolescent medicine clinicians, and cannabis clinicians managing adolescents who use cannabis, alcohol, or nicotine alongside depressive or anxiety symptoms

Primary Topic
A prespecified secondary analysis of a randomized clinical trial testing a codesigned digital behavioral health game against an active control among 532 adolescents recruited from Connecticut school-based health programs, with past-30-day [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) as one of several eligibility criteria, published in JAMA Network Open, August 2026

Source
[Read the study on PubMed](https://pubmed.ncbi.nlm.nih.gov/42606863/)

Table of Contents

- [A School-Based Digital Game Modestly Reduced Adolescent Depression: What Clinicians Treating Cannabis-Using Teens Should Know](#A_School-Based_Digital_Game_Modestly_Reduced_Adolescent_Depression_What_Clinicians_Treating_Cannabis-Using_Teens_Should_Know)
- [How to Read a Secondary Analysis With an Exploratory Mediation Finding](#How_to_Read_a_Secondary_Analysis_With_an_Exploratory_Mediation_Finding)[A Four-Step Reading Frame](#A_Four-Step_Reading_Frame)
- [A Depression Benefit, Not a Cannabis Finding: Eight Ways to Read This Trial](#A_Depression_Benefit_Not_a_Cannabis_Finding_Eight_Ways_to_Read_This_Trial)[What This Means If Your Teen Uses Cannabis and Also Seems Down](#What_This_Means_If_Your_Teen_Uses_Cannabis_and_Also_Seems_Down)
- [A Scalable Option Worth Knowing, Not a Cannabis Intervention](#A_Scalable_Option_Worth_Knowing_Not_a_Cannabis_Intervention)
- [Why a Non-Cannabis Study Still Belongs on a Cannabis Clinician’s Radar](#Why_a_Non-Cannabis_Study_Still_Belongs_on_a_Cannabis_Clinician8217s_Radar)
- [A Real Effect, but a Small One, With an Exploratory Mediation Claim](#A_Real_Effect_but_a_Small_One_With_an_Exploratory_Mediation_Claim)
- [School-Based Health Programs Are the Right Place to Test This](#School-Based_Health_Programs_Are_the_Right_Place_to_Test_This)
- [Secondary Outcomes, Self-Report, and Multiple Comparisons](#Secondary_Outcomes_Self-Report_and_Multiple_Comparisons)
- [A Template for Testing Digital Mental Health Tools Rigorously](#A_Template_for_Testing_Digital_Mental_Health_Tools_Rigorously)
- [Scalable Tools Matter Even When Effects Are Small](#Scalable_Tools_Matter_Even_When_Effects_Are_Small)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## A School-Based Digital Game Modestly Reduced Adolescent Depression: What Clinicians Treating Cannabis-Using Teens Should Know

A randomized trial of 532 adolescents recruited in part for past-30-day cannabis, alcohol, or nicotine use found that a codesigned digital behavioral health game modestly reduced depressive symptoms over 12 months compared with an active control, with no cannabis-use outcome measured and no benefit detected for anxiety.

What This Study Teaches Us
This trial shows that a scalable, school-delivered digital intervention, tested against an active control rather than no treatment, was associated with a small but statistically significant and durable reduction in depressive symptoms among adolescents, some of whom reported recent cannabis or other substance use as part of trial eligibility. The game did not measure or target [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) directly, and no anxiety benefit was detected, which underscores that this is a general [adolescent mental health](https://cedclinic.com/conduct-disorder-substance-use-disorders-teens/) intervention rather than a cannabis-specific one.

Why This Matters
Clinicians managing adolescents who use cannabis often see mood symptoms and cannabis use as intertwined, and self-medication of anxiety or depression is a commonly reported reason teens give for cannabis use. This trial does not test cannabis outcomes, but it offers a rigorously controlled option for reducing depressive symptoms at the population level in exactly the kind of substance-use-inclusive adolescent population many family medicine and cannabis-focused practices serve, without medication or cannabis-focused counseling.

Study Snapshot

Study Type
Prespecified secondary analysis of a parallel-group, active-controlled randomized clinical trial (CONSORT-reported)

Population
532 adolescents ages 16 to 19 (mean age 16.6, SD 0.7) recruited from 15 Connecticut school-based health programs, October 2021 to February 2024

Eligibility
No prior opioid misuse, plus past-30-day use of alcohol, cannabis, nicotine, or other nonopioid substances, or a positive screen for depressive or anxiety symptoms

Intervention
PlaySmart, a codesigned digital behavioral health game delivered on tablets in 40- to 60-minute sessions over up to 6 weeks (n=269)

Control
Active control using commercially available games (e.g., The Sims, Papers Please) matched for time and attention (n=263)

Measures
Depressive symptoms (PHQ-8) and anxiety symptoms (GAD-7); secondary psychosocial outcomes included beliefs about psychological services (BAPS), help-seeking intentions (GHSQ), and emotion regulation (S-DERS)

Follow-Up
Baseline, 6 weeks, and 3, 6, and 12 months

Depression Finding
Adjusted PHQ-8 scores 1.12 points lower in the intervention group at 12 months (95% CI, -1.85 to -0.38; P=.002; Cohen d=0.21)

Anxiety Finding
No significant group-by-time interaction for GAD-7 (F3,1308=1.69; P=.17)

Adverse Events
2 mild adverse events (brief gameplay-related discomfort); no serious harms

Journal
JAMA Network Open

Published
August 3, 2026

DOI
10.1001/jamanetworkopen.2026.29173

PMID
42606863

Clinical Bottom Line
In a randomized trial of 532 adolescents recruited in part for recent cannabis, alcohol, or nicotine use, a codesigned digital behavioral health game produced a modest but statistically significant and durable reduction in depressive symptoms over 12 months compared with an active control, with no detected benefit for anxiety and no measurement of cannabis use as an outcome.

What the Trial Tested

Researchers conducted a prespecified secondary analysis of a randomized clinical trial testing PlaySmart, a codesigned digital behavioral health game originally built to prevent opioid misuse, against an active control among 532 adolescents recruited from 15 school-based health programs in Connecticut.

Eligible teens were 16 to 19 years old with no history of opioid misuse, and qualified by reporting past-30-day use of alcohol, cannabis, nicotine, or other nonopioid substances, or by screening positive for depressive or anxiety symptoms, meaning cannabis use was one of several possible entry points rather than a study focus.

Depressive Symptoms Improved Modestly, and the Benefit Grew Over a Year

Depressive symptoms, measured with the 8-item Patient Health Questionnaire (PHQ-8), showed a significant group-by-time interaction (F3,1308=2.93; P=.03), with intervention participants scoring 1.12 points lower than control participants at 12 months (95% CI, -1.85 to -0.38; P=.002; Cohen d=0.21).

The effect size was small, consistent with universal prevention programs aimed at broad populations rather than diagnosed clinical depression, and the authors describe the pattern, a benefit that widened over a year rather than appearing immediately, as consistent with a possible sleeper effect in which skills learned during gameplay become more usable once initial skepticism about a game-based intervention fades.

Anxiety and Most Other Outcomes Showed No Measurable Benefit

The group-by-time interaction for anxiety symptoms (GAD-7) was not significant (F3,1308=1.69; P=.17), and no between-group differences in anxiety emerged at any follow-up assessment.

Help-seeking intentions and emotion regulation also showed no significant intervention effect, and moderation analyses found no differential benefit by sex, grade level, food insecurity, familial substance misuse, or peer substance-use norms.

A Possible Mechanism: Early Shifts in Beliefs About Seeking Help

Intervention participants reported more favorable beliefs about psychological services (BAPS) immediately after the 6-week gameplay period (adjusted difference, 0.03; 95% CI, 0.01-0.05; P=.003), and this difference remained similar at later assessments even though the overall group-by-time interaction for BAPS was not significant.

An exploratory, post hoc mediation analysis found that this early improvement in BAPS partially explained the depressive symptom reduction observed at 6 months (average causal mediation effect, -0.13; 95% CI, -0.30 to -0.01; P=.02), though no mediation effect was detected at 3 or 12 months, and the authors describe this analysis as hypothesis-generating rather than confirmatory.

What the Trial Does Not Tell Us About Cannabis

This trial did not measure cannabis use as an outcome, did not report results stratified by baseline cannabis use, and did not test whether the game changed cannabis use, craving, or related behaviors; past-30-day cannabis use was only one of several qualifying eligibility criteria, alongside alcohol, nicotine, other nonopioid substances, or elevated mood or anxiety symptoms alone.

Readers should not interpret this trial as evidence that the game reduces cannabis use or that it was designed with cannabis specifically in mind. It is a general [adolescent mental health](https://cedclinic.com/conduct-disorder-substance-use-disorders-teens/) intervention studied in a population that, by design, regularly includes substance-using teens.

How Strong Is This Evidence?
This is a randomized, CONSORT-reported clinical trial with an active, attention-matched control group rather than a passive or no-treatment comparison, longitudinal follow-up to 12 months, and intention-to-treat mixed-effects modeling with a participant-level random intercept. The sample was large (532 participants) and racially and ethnically diverse, drawn from school-based health programs that reach adolescents who often face barriers to traditional mental health care, and analysts remained blinded to outcome data until database lock.

Where This Paper Deserves Skepticism
Depressive and anxiety outcomes were prespecified secondary end points, not the outcomes the original trial was powered to detect, and the psychosocial mediation analysis was exploratory and conducted post hoc. All outcome measures relied on adolescent self-report without biological or collateral verification, and the trial tested multiple secondary and exploratory outcomes without a described correction for multiple comparisons, which raises the chance that some findings, including the borderline mediation result at 6 months (P=.02), reflect chance rather than a true effect. The 12-month depression benefit, while statistically significant, corresponds to a small effect size (Cohen d=0.21) that may not represent an individually meaningful change for any given adolescent.

What This Paper Does Not Show
This trial does not show that the game reduces cannabis use, craving, or any other substance-use outcome; cannabis use was never assessed as a trial outcome. It does not show a benefit for anxiety symptoms, help-seeking intentions, or emotion regulation, and it does not establish that the depressive symptom benefit would hold in adolescents recruited outside school-based health programs, in younger or older age groups, or in settings without dedicated program staff to deliver the intervention.

How This Fits With the Broader Clinical Conversation

This trial adds to a growing but still limited literature on serious games and interactive digital media for adolescent mental health, most of which has tested short-term effects or used passive comparison groups that leave open questions about whether apparent benefits reflect a game’s specific content or simply attention and novelty.

By using an active, time-matched control of commercially available games, this trial offers a more rigorous test of content-specific effects than many earlier digital mental health studies, though its authors are explicit that the psychosocial mechanism findings remain exploratory and require replication in preregistered studies.

Dr. Caplan’s Take

*What I find useful about this trial is the population it was run in. School-based health programs reach exactly the mix of teens I worry about most, adolescents who may be using cannabis, alcohol, or nicotine and who also carry real depressive symptoms, often without ever reaching specialty mental health care. A scalable, low-cost digital tool that modestly reduces depressive symptoms in that setting, tested against an active control rather than nothing, deserves attention.*

*I want to be direct about what this study is not. It is not a cannabis trial. Cannabis use got a teenager into the study alongside several other possible entry points, but nothing here was measured, analyzed, or reported about cannabis use itself. I would not tell a patient or a parent that this game treats cannabis use or reduces the urge to use it. What I would say is that if a cannabis-using adolescent in my practice is also dealing with depressive symptoms, a scalable, evidence-supported digital tool like this is a reasonable option to know about, alongside, not instead of, direct conversation about their cannabis use.*

What a Careful Reader Should Take Away
A rigorous randomized trial found that a codesigned digital behavioral health game modestly and durably reduced depressive symptoms over 12 months among adolescents recruited in part for recent cannabis, alcohol, or nicotine use, but the trial did not measure or target cannabis use itself, and its anxiety and psychosocial findings were mostly null or exploratory.

Evidence Interpretation Guide

## How to Read a Secondary Analysis With an Exploratory Mediation Finding

This trial’s headline result, a modest depressive symptom reduction against an active control, is genuinely well supported. Its secondary claim, that improved beliefs about seeking help partly explain that benefit, rests on much thinner statistical ground.

Four checks keep the trial’s real contribution from being overstated in either direction, toward cannabis relevance it does not have, or away from the depression benefit it does show.

### A Four-Step Reading Frame

**Separate the primary trial from this secondary analysis**Depression and anxiety were prespecified secondary outcomes; the original trial was powered for opioid-related outcomes, not these.

**Note what was never measured**Cannabis use was an eligibility criterion only. No cannabis outcome, craving, or use-frequency data appears anywhere in this analysis.

**Treat the mediation finding as hypothesis-generating**The BAPS-to-depression mediation effect was exploratory, post hoc, and only significant at one of three follow-up points (P=.02 at 6 months).

**Weigh the effect size, not just the p-value**A statistically significant 1.12-point PHQ-8 difference (Cohen d=0.21) is real but small, typical of universal prevention programs.

The Research Question
Does a codesigned digital behavioral health game reduce depressive and anxiety symptoms in adolescents recruited from school-based health programs, some of whom report recent cannabis, alcohol, or nicotine use, compared with an active control?

The Patient Question
If my teenager uses cannabis and also seems depressed, could a game like this help, and does it address the cannabis use itself?

The Bottom Line
The game showed a modest, durable depression benefit in this population, but it was not designed or tested to change cannabis use, and any depression benefit should be treated as one part of a broader conversation about a teen’s substance use, not a substitute for it.

CED Perspective Lens

## A Depression Benefit, Not a Cannabis Finding: Eight Ways to Read This Trial

This trial modestly improved adolescent depression in a population that regularly includes cannabis-using teens, but it never measured cannabis use itself. These eight perspectives keep that distinction clear while still drawing out what is genuinely useful here.

Lens Overview
Eight perspectives separate this trial’s well-supported depression finding from its exploratory mediation claim and its limited, indirect relevance to cannabis use itself.

#### What This Means If Your Teen Uses Cannabis and Also Seems Down

This trial found that a school-delivered digital game modestly reduced depressive symptoms over a year among teens recruited in part for recent cannabis, alcohol, or nicotine use, but it did not test whether the game changes cannabis use itself, so it is not a cannabis treatment or a substitute for talking directly about substance use.

If your teenager is struggling with low mood and also uses cannabis, this study suggests that scalable, school-based digital tools can help with the mood piece, while the cannabis use still needs its own direct conversation with a clinician who understands both issues.

Lens takeaway
A digital mental health tool can help with mood, but it does not address cannabis use on its own.

#### A Scalable Option Worth Knowing, Not a Cannabis Intervention

This trial supports a codesigned digital game as one low-cost, scalable option for reducing depressive symptoms in adolescents seen in school-based health programs, a setting that overlaps heavily with teens who use cannabis, alcohol, or nicotine.

Clinicians should be precise with patients and families about what this study does and does not show: it measured mood outcomes, not cannabis use, so it belongs in a broader treatment plan rather than as a stand-alone response to [adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/).

Lens takeaway
Consider this as an adjunct mood-focused tool, not a cannabis-use intervention.

#### Why a Non-Cannabis Study Still Belongs on a Cannabis Clinician’s Radar

Adolescents who self-medicate anxiety or depression with cannabis are a familiar population in cannabis-focused practice, and this trial was conducted in a setting, school-based health programs, that regularly serves exactly those teens, even though cannabis use itself was never analyzed.

Knowing that a validated, active-controlled digital tool can modestly improve depressive symptoms gives cannabis clinicians another option to discuss with families who want to address mood symptoms without adding medication or without cannabis being the only tool on the table.

Lens takeaway
Use this as a mood-focused adjunct option to raise with cannabis-using adolescent patients, not as cannabis-specific evidence.

#### A Real Effect, but a Small One, With an Exploratory Mediation Claim

The 12-month depression finding is statistically solid, a significant group-by-time interaction (P=.03) and a between-group difference with a tight confidence interval (95% CI, -1.85 to -0.38; P=.002), though the effect size itself was small (Cohen d=0.21).

The mediation analysis linking early belief change to later depression reduction was exploratory, post hoc, and significant at only one of three follow-up points (P=.02 at 6 months), which means it should be read as a plausible mechanism worth testing, not a confirmed pathway.

Lens takeaway
Trust the depression finding’s statistics; treat the mediation story as a hypothesis, not a conclusion.

#### School-Based Health Programs Are the Right Place to Test This

Delivering a mental health intervention inside school-based health programs reaches adolescents, including those from historically underserved racial and ethnic groups who reported some of the highest rates of sadness and hopelessness nationally, who might not otherwise access mental health care.

The trial’s diverse sample, 45.3% Black or African American and 38.0% Hispanic or Latinx participants, and its use of an active rather than passive control, make this a stronger test of real-world feasibility than many earlier school-based digital mental health studies.

Lens takeaway
This delivery model reaches adolescents who often lack other access to [mental health support](https://cedclinic.com/social-support-substance-use-stigmatized-populations/).

#### Secondary Outcomes, Self-Report, and Multiple Comparisons

Depression and anxiety were prespecified secondary outcomes in a trial originally powered around opioid-related endpoints, and every outcome relied on adolescent self-report without biological or collateral verification.

The trial tested several secondary and exploratory outcomes without a described correction for multiple comparisons, which raises real questions about how many of these findings, particularly the borderline mediation result, would hold up in a study purpose-built and powered to test them. A study purpose-built and adequately powered to test that mediation pathway directly would give clinicians far more confidence before treating it as a real mechanism.

Lens takeaway
Secondary, self-reported, multiple-comparison findings call for replication before real clinical confidence.

#### A Template for Testing Digital Mental Health Tools Rigorously

This trial’s active, time-and-attention-matched control group is a methodological strength many digital mental health studies lack, and it allows a more credible test of whether the game’s specific content, rather than novelty or attention, drove the depression benefit.

The authors’ own framing points to the clear next step: a study purpose-built and powered to test the BAPS-mediation pathway directly, ideally with objective corroboration of self-reported outcomes and preregistered subgroup analyses.

Lens takeaway
This is a well-controlled secondary analysis that should be followed by a purpose-built confirmatory trial.

#### Scalable Tools Matter Even When Effects Are Small

A 1.12-point PHQ-8 difference will not feel dramatic to any one adolescent, but delivered at scale through existing school-based health infrastructure, a modest, low-cost, low-burden intervention like this can meaningfully shift population-level depressive symptom burden.

The relevant public health caution is framing: this trial should not be described as a cannabis intervention or as evidence that digital games reduce substance use, since neither was tested, and overstating its scope would misrepresent a genuinely useful but narrowly defined finding.

Lens takeaway
Communicate this as a scalable mood intervention, not a cannabis-use intervention.

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

[Leave a Message](https://cedclinic.com/contact/)
[Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
[Medical Consulting](https://cedclinic.com/book/)
[Cannabis Care](https://cedclinic.com/book/)

[https://cedclinic.com/contact/](https://cedclinic.com/contact/)

Share this Evidence Watch

[X](https://twitter.com/intent/tweet?text=A+School-Based+Digital+Game+Modestly+Reduced+Adolescent+Depression%3A+What+Clinicians+Treating+Cannabis-Using+Teens+Should+Know&url=https%3A%2F%2Fcedclinic.com%2Fdigital-behavioral-health-game-adolescent-depression-rct%2F)
[LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fdigital-behavioral-health-game-adolescent-depression-rct%2F)
[BlueSky](https://bsky.app/intent/compose?text=A+School-Based+Digital+Game+Modestly+Reduced+Adolescent+Depression%3A+What+Clinicians+Treating+Cannabis-Using+Teens+Should+Know%20https%3A%2F%2Fcedclinic.com%2Fdigital-behavioral-health-game-adolescent-depression-rct%2F)
[Instagram](https://www.instagram.com/drcaplan/)
[Substack](https://doctorapprovedcannabis.substack.com/)
[RSS](https://cedclinic.com/feed/)

Source: [Barry CM, Boomer T, Haile K, Xie H, Fiellin LE. A Digital Behavioral Health Game for Adolescent Mental Health: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2026 Aug 3. DOI: 10.1001/jamanetworkopen.2026.29173. PMID: 42606863.](https://pubmed.ncbi.nlm.nih.gov/42606863/)

Related Reading at CED Clinic
Continue exploring the evidence

[Real-Time Monitoring of Youth Substance Use: What a New Preprint Review of 43 Studies Found](https://cedclinic.com/real-time-monitoring-youth-substance-use-review/)

CED’s earlier coverage of digital, real-time monitoring and intervention tools for youth substance use, including cannabis, useful context for how digital approaches are being tested across adolescent substance-use and mental-health settings.

[Read the youth substance-use monitoring review](https://cedclinic.com/real-time-monitoring-youth-substance-use-review/)

[Exploring Digital Cannabis Harm Reduction in First-Episode Psychosis](https://cedclinic.com/digital-cannabis-harm-reduction-first-episode-psychosis/)
A related look at a digital app aimed at cannabis harm reduction in a young, clinically vulnerable population, offering a contrasting example of a digital tool that does target cannabis use directly.

[Read about digital cannabis harm reduction](https://cedclinic.com/digital-cannabis-harm-reduction-first-episode-psychosis/)

[Virtual Program Reduces Cannabis and Alcohol Use in Native American Emerging Adults](https://cedclinic.com/culturally-grounded-virtual-substance-use-intervention-native-american/)
A randomized trial of a culturally grounded virtual intervention that reduced both cannabis and alcohol use among young adults, useful comparison for how digital delivery models perform across different adolescent and young-adult populations.

[Read the Native American emerging adults trial coverage](https://cedclinic.com/culturally-grounded-virtual-substance-use-intervention-native-american/)

## Frequently Asked Questions

What did this trial test?

Researchers tested PlaySmart, a codesigned digital behavioral health game, against an active control of commercially available games among 532 adolescents recruited from Connecticut school-based health programs, following them for 12 months to assess depressive and anxiety symptoms and related psychosocial outcomes.

Was this a study about cannabis?

No. Cannabis use was one of several possible eligibility criteria, alongside alcohol, nicotine, other nonopioid substance use, or elevated depression or anxiety symptoms alone. The trial never measured cannabis use, craving, or related outcomes.

Did the digital game reduce depression?

Yes, modestly. At 12 months, adjusted PHQ-8 depression scores were 1.12 points lower in the intervention group than the control group (95% CI, -1.85 to -0.38; P=.002; Cohen d=0.21), with a significant group-by-time interaction (P=.03).

Did the game help with anxiety symptoms?

No significant benefit was found. The group-by-time interaction for anxiety symptoms (GAD-7) was not significant (P=.17), and no between-group differences emerged at any follow-up assessment.

How was the game different from a typical screen-time control?

The control group played commercially available games, such as The Sims and Papers Please, matched for time and attention, which is a more rigorous comparison than a passive or no-treatment control because it accounts for the effects of novelty and screen engagement alone.

What might explain why depressive symptoms improved?

An exploratory, post hoc mediation analysis found that early improvements in beliefs about seeking psychological help, measured 6 weeks after gameplay, partially explained the depression reduction seen at 6 months, though this mediation effect was not detected at 3 or 12 months.

Who were the adolescents in this trial?

532 teens ages 16 to 19 (mean age 16.6) recruited from 15 Connecticut school-based health programs; 45.3% identified as Black or African American, 33.6% as White, and 38.0% as Hispanic or Latinx, with 53.4% identifying as male.

Were there any safety concerns?

Two mild adverse events were documented, both involving brief discomfort during or after gameplay judged as possibly related to the intervention. No serious or unexpected harms occurred.

What are the main limitations of this trial?

Depression and anxiety were prespecified secondary outcomes rather than the trial’s original powered endpoint, all measures relied on adolescent self-report, the mediation analysis was exploratory and post hoc, and the trial did not describe correction for multiple comparisons across its several secondary outcomes.

Should this change how clinicians manage cannabis-using adolescents?

This trial offers a scalable, evidence-supported option to consider for adolescents with depressive symptoms, including those recruited from substance-use-inclusive populations, but it does not address cannabis use directly and should not replace direct clinical conversation about a teen’s cannabis use.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).